Pair page
Nesfatin-1 with Semaglutide
Mechanism-tag overlap and published literature for Nesfatin-1 and Semaglutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
hypothalamic-anorexigenic-regulator
glp-1-receptor-agonistmetabolic
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Nesfatin-1 and Semaglutide have published these mechanism-level observations. Not a co-administration recommendation.
GLP-1-axis drugs are the clinically validated anorexigenic therapeutics. Mechanistically independent of nesfatin-1 (gut-brain vs hypothalamic oxytocin-POMC). In research terms, the two pathways can be interrogated for additive versus overlapping effects.
Quick facts
Nesfatin-1
Semaglutide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2013 | Nesfatin-1 | Dong J, Xu H, Xu H, Wang PF, Cai GJ, Song HF, Wang CC, Dong ZT, Ju YJ, Jiang ZY. Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice. PLoS One. 2013;8(12):e83397. PMID: 24391762. PMID 24391762 | preclinical, in vivo |
| 2010 | Nesfatin-1 | Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK, Randeva HS. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology. 2010;151(7)… PMID 20427481 | preclinical, in vivo |
| 2008 | Nesfatin-1 | Kohno D, Nakata M, Maejima Y, Shimizu H, Sedbazar U, Yoshida N, Dezaki K, Onaka T, Mori M, Yada T. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology. 2008;149(3):12… PMID 18048495 | preclinical, in vivo |
| 2013 | Nesfatin-1 | Goebel-Stengel M, Wang L. Central and peripheral expression and distribution of NUCB2/nesfatin-1. Curr Pharm Des. 2013;19(39):6935-6940. PMID: 23537086. PMID 23537086 | pharmacology |
| 2014 | Nesfatin-1 | Yosten GL, Samson WK. Neural circuitry underlying the central hypertensive action of nesfatin-1: melanocortins, corticotropin-releasing hormone, and oxytocin. Am J Physiol Regul Integr Comp Physiol. 2014;306(10):R722-R727. PMID: 24598461. PMID 24598461 | research article |
| 2014 | Nesfatin-1 | Dong J, Xu H, Wang PF, Cai GJ, Song HF, Wang CC, Dong ZT, Ju YJ, Jiang ZY. Nesfatin-1 influences the excitability of glucosensing neurons in the dorsal vagal complex and inhibits food intake. PLoS One. 2014;9(6):e98966. PMID: 24896641. PMID 24896641 | research article |
| 2013 | Nesfatin-1 | Stengel A, Taché Y. Role of brain NUCB2/nesfatin-1 in the regulation of food intake. Curr Pharm Des. 2013;19(39):6955-6959. PMID: 23537088. PMID 23537088 | research article |
| 2013 | Nesfatin-1 | Aydin S. Multi-functional peptide hormone NUCB2/nesfatin-1. Endocrine. 2013;44(2):312-325. PMID: 23526235. PMID 23526235 | research article |
| 2011 | Nesfatin-1 | Stengel A, Taché Y. Minireview: Nesfatin-1 — an emerging new player in the brain-gut, endocrine, and metabolic axis. Endocrinology. 2011;152(11):4033-4038. PMID: 21862618. PMID 21862618 | research article |
| 2010 | Nesfatin-1 | Stengel A, Goebel M, Wang L, Taché Y. Ghrelin, des-acyl ghrelin and nesfatin-1 in gastric X/A-like cells: role as regulators of food intake and body weight. Peptides. 2010;31(2):357-369. PMID: 19944123. PMID 19944123 | research article |
| 2010 | Nesfatin-1 | Yosten GL, Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am J Physiol Regul Integr Comp Physiol. 2010;298(6):R1642-R1647. PMID: 20335376. PMID 20335376 | research article |
| 2010 | Nesfatin-1 | García-Galiano D, Navarro VM, Gaytan F, Tena-Sempere M. Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. J Mol Endocrinol. 2010;45(5):281-290. PMID: 20823113. PMID 20823113 | research article |
| 2024 | Semaglutide | Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. PMID: 38785209. PMID 38785209 | human trial |
| 2023 | Semaglutide | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. PMID 37952131 | human trial |
| 2022 | Semaglutide | Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID: 36216945. PMID 36216945 | human trial |
| 2022 | Semaglutide | Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150. PMID: 35015037. PMID 35015037 | human trial |
| 2021 | Semaglutide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. PMID 33567185 | human trial |
| 2021 | Semaglutide | Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417. PMID 33667417 | human trial |
| 2021 | Semaglutide | Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. PMID: 33625476. PMID 33625476 | human trial |
| 2021 | Semaglutide | Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33755728. PMID 33755728 | human trial |
| 2021 | Semaglutide | Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID: 33185364. PMID 33185364 | human trial |
| 2019 | Semaglutide | Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. PMID: 31186300. PMID 31186300 | human trial |
| 2016 | Semaglutide | Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186. PMID 27633186 | human trial |
| 2019 | Semaglutide | Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. PMID: 31031702. PMID 31031702 | mechanism / discovery |
Related pair pages
More research context
Frequently asked
Have Nesfatin-1 and Semaglutide been studied together?
Researchers have published mechanistic-level co-administration discussion of Nesfatin-1 and Semaglutide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Nesfatin-1 and Semaglutide share?
Nesfatin-1 and Semaglutide do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Nesfatin-1 and Semaglutide?
Nesfatin-1: Not approved. Semaglutide: Approved (2017). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Nesfatin-1 and Semaglutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Nesfatin-1 profile and the Semaglutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026